In Q2 2025, BioMérieux saw revenues rise 1% year-over-year to €945.9 million, driven by molecular biology clinical application gains offsetting weaknesses in immunoassays. Sales of molecular biology products increased 10% at constant exchange rates, benefiting from BioFire panels and the SpotFire system, whose installed base more than tripled to 4,600 units. Meanwhile, respiratory panel sales grew slightly, challenged by high respiratory infection prevalence last year. The company acquired SpinChip Diagnostics and Day Zero Diagnostics assets, investing in next-generation platforms. Profitability gains reflect the strategic GO 28 plan implementation amid global economic complexities.